Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ODI Pharma ABXSAT:ODI -11.02%46 PB Ratio is 23.06 as of Jul. 16, 2026, which is 60% above its 10-year median of 14.41. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.52 (Significantly Undervalued). Among 922 Drug Manufacturers companies, ODI Pharma AB ranks worse than 98.05% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-16), ODI Pharma AB's share price is kr2.26. ODI Pharma AB's Book Value per Share for the quarter that ended in Mar. 2026 was kr0.10. Hence, ODI Pharma AB's PB Ratio of today is 23.06.
Good Sign:
ODI Pharma AB stock PB Ratio (=23.47) is close to 3-year low of 21.18.
The historical rank and industry rank for ODI Pharma AB's PB Ratio or its related term are showing as below:
XSAT:ODI'
s PB Ratio Range Over the Past 10 Years
Min: 2.94 Med: 14.41 Max: 225
Current: 23.07
During the past 7 years, ODI Pharma AB's highest PB Ratio was 225.00. The lowest was 2.94. And the median was 14.41.
XSAT:ODI's PB Ratio is ranked worse than 98.05% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.955
vs XSAT:ODI: 23.07
During the past 12 months, ODI Pharma AB's average Book Value Per Share Growth Rate was 84.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -66.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -54.80% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of ODI Pharma AB was 31.80% per year. The lowest was -66.40% per year. And the median was -49.95% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ODI Pharma AB PB Ratio Related Terms
ODI Pharma AB PB Ratio Historical Data
* Premium members only.
The historical data trend for ODI Pharma AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ODI Pharma AB PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where ODI Pharma AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
ODI Pharma AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ODI Pharma AB (XSAT:ODI) has a PB Ratio of 23.06 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ODI Pharma AB and its competitors. This is 60% above median its historical median of 14.41. Over the past decade, ODI Pharma AB's PB Ratio has ranged from 2.94 to 225.00. According to the industry distribution chart, ODI Pharma AB ranks #904 out of 922 companies in the Drug Manufacturers industry, placing it in the top 98%.
Is ODI Pharma AB's PB Ratio too high?
ODI Pharma AB's current PB Ratio of 23.06 is 60% above median its 10-year median of 14.41. Over the past 10 years, this metric has ranged from a low of 2.94 to a high of 225.00. The Drug Manufacturers industry median PB Ratio is 1.96. ODI Pharma AB's value of 23.06 is 1079.5% above this industry median. Based on the distribution chart, ODI Pharma AB ranks #904 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ODI Pharma AB ranks #904 out of 922 companies for PB Ratio. This places ODI Pharma AB in the lower half of its industry. The industry median PB Ratio is 1.96. ODI Pharma AB's value of 23.06 is 1079.5% above this benchmark. Historically, ODI Pharma AB's own PB Ratio has ranged from 2.94 to 225.00 over the past decade. While the company's 10-year median is 14.41 vs. the industry median of 1.96, ODI Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ODI Pharma AB's current PB Ratio of 23.06 is 1079.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ODI Pharma AB and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ODI Pharma AB's current PB Ratio is 23.06, which is 60% above median its own 10-year median of 14.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.52, compared to a current price of kr2.26 — trading 76.3% below its estimated fair value. The current PB Ratio is 23.06, which is 60% above median its 10-year median of 14.41 and 1079.5% above the Drug Manufacturers industry median of 1.96. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current PB Ratio is 23.06 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?
Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued.
The current stock price of kr2.26 is trading 76.3% below its estimated GF Value™ of kr9.52.
GuruFocus considers ODI Pharma AB to be Significantly Undervalued.
Key valuation signals for XSAT:ODI:
PB Ratio: 23.06 (60% above median its 10-year median of 14.41)
GF Value™: kr9.52 vs. price of kr2.26 (76.3% below fair value)
Industry Position: 1079.5% above the Drug Manufacturers median (#904 of 922)
No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ODI has been successfully added to your 
